A Simple LC-MS/MS Method for the Quantification of PDA-66 in Human Plasma

Area of Science:

• Pharmacology and Therapeutics
• Analytical Chemistry
• Cancer Biology

Background:

• Cancer treatment relies on chemotherapy and targeted therapies.
• PDA-66, a glycogen synthase kinase 3β inhibitor analogue, exhibits preclinical anticancer effects.
• Key anticancer mechanisms of PDA-66 involve cell cycle, DNA replication, and p53 signaling.

Purpose of the Study:

• To develop and validate a sensitive LC-MS/MS method for quantifying PDA-66 in human plasma.
• To establish a reliable method for therapeutic drug monitoring of PDA-66.
• To assess the utility of the method for quantifying PDA-66 in animal plasma and sera.

Main Methods:

• Development of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay.
• Quantification of PDA-66 in human plasma samples.
• Method validation and application to mouse plasma and sera.

Main Results:

• A sensitive LC-MS/MS method for PDA-66 quantification was established.
• The method achieved a lower limit of quantification of 2.5 nM in human plasma.
• The method was successfully validated and applied to mouse plasma and sera.

Conclusions:

• The developed LC-MS/MS method enables sensitive and reliable quantification of PDA-66.
• This method is suitable for therapeutic drug monitoring in cancer patients.
• The validated method supports preclinical and clinical studies of PDA-66.